Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,263 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 111
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Femoral Shaft Fracture, Tibial Shaft Fracture
Interventions: GIK solution, Isotonic Normal Saline Solution; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV -1 Infection
Interventions: GS-0415, GS-0415 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 734,383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autism
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 15 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Indianapolis, Indiana • Lexington, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo, Real-time Neurofeedback fMRI task pre- and post-RCT; Drug · Behavioral
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bipolar I Disorder
Interventions: LB-102, Placebo; Drug · Other
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more

Conditions: Cachexia
Interventions: AV-380, Placebo; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Pancreatitis
Interventions: aprepitant, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Kidney Diseases, Endothelial Dysfunction
Interventions: Resveratrol, Placebo; Dietary Supplement · Other
Lead sponsor: Diana Jalal; Other
Eligibility: 45 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Helicobacter Pylori
Interventions: Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Fibromyalgia
Interventions: GRT9906, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: DeLand, Florida • Charlotte, North Carolina • Medford, Oregon + 2 more

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuropathy; Radicular, Lumbar, Lumbosacral, Failed Back Surgery Syndrome, Spinal Stenosis, Herniated Disc
Interventions: Pregabalin, Sugar Pill; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: MT-501; Drug
Lead sponsor: Mirador Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Coronary Artery Disease
Interventions: Omacor, omega-3 fatty acids in CAD patients; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 50 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Peyronie Disease, Sexual Dysfunction, Physiological, Sexual Dysfunction Male, Genital Diseases, Male
Interventions: Autologous Platelet-Rich Plasma (PRP), Placebo (Normal Saline); Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lactose Intolerance
Interventions: Lactobacillus acidophilus MPH734, Placebo; Dietary Supplement
Lead sponsor: Lemuel W. Taylor IV; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Cardiovascular Disease, Vitamin D Deficiency
Interventions: Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Depression, Depression, Anxiety, Inflammation
Interventions: Freeze Dried Blueberry Powder - 71717, USHBC Blueberry Placebo Formula #114; Dietary Supplement
Lead sponsor: Louisiana State University, Baton Rouge; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Cottonport, Louisiana • Marksville, Louisiana

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more

Conditions: Cocaine Dependence
Interventions: Doxazosin, Modafinil, cocaine, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions: Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 40 Years to 69 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

MAGIK for Femoral/Tibial Shaft Fractures

Study of GS-0415 and How It Works in People With HIV

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

Study of Neural Responses Induced by Antidepressant Effects

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

A Phase 1 Study of AV-380 in Healthy Subjects

A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Resveratrol and Vascular Function in CKD

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Efficacy of Pregabalin in Patients With Radicular Pain

A First-in-Human Single and Multiple Ascending Dose Study of MT-501

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

PRP for Treatment of Peyronie's Disease

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D

Effect of Whole Blueberry Powder Consumption on Depression in a Central Louisiana Population

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Complementary Combination Therapy for Cocaine Dependence

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood